Assignee
MEDAREX INC
US·87 granted patents·22 pending applications·11,322 citations·filing 1994–2013
Top patents by PatentIndex Score
109 records- 0199US9102725B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)MEDAREX INC·Filed 2013·Granted Aug 11, 2015·120 cites·31 claims
- 0299US8383796B2Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1)MEDAREX INC·Filed 2011·Granted Feb 26, 2013·355 cites·31 claims
- 0399US8017114B2Human CTLA-4 antibodies and their usesMEDAREX INC·Filed 2009·Granted Sep 13, 2011·199 cites·33 claims
- 0499US8008449B2Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeuticsMEDAREX INC·Filed 2006·Granted Aug 30, 2011·2.2k cites·23 claims
- 0599US7943743B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)MEDAREX INC·Filed 2006·Granted May 17, 2011·1.5k cites·26 claims
- 0699US7605238B2Human CTLA-4 antibodies and their usesMEDAREX INC·Filed 2001·Granted Oct 20, 2009·353 cites·32 claims
- 0799US7501552B2Transgenic non-human animals for producing chimeric antibodiesMEDAREX INC·Filed 2004·Granted Mar 10, 2009·182 cites·3 claims
- 0899US6984720B1Human CTLA-4 antibodiesMEDAREX INC·Filed 2000·Granted Jan 10, 2006·897 cites·14 claims
- 0999US5922845ATherapeutic multispecific compounds comprised of anti-Fcα receptor antibodiesMEDAREX INC·Filed 1996·Granted Jul 13, 1999·448 cites·24 claims
- 1098US7910798B2Transgenic animals expressing chimeric antibodies for use in preparing human antibodiesMEDAREX INC·Filed 2007·Granted Mar 22, 2011·130 cites·5 claims
- 1198US7517903B2Cytotoxic compounds and conjugatesMEDAREX INC·Filed 2005·Granted Apr 14, 2009·161 cites·19 claims
- 1298US7507420B2Peptidyl prodrugs and linkers and stabilizers useful thereforMEDAREX INC·Filed 2005·Granted Mar 24, 2009·148 cites·32 claims
- 1398US7498302B2Disulfide prodrugs and linkers and stabilizers useful thereforMEDAREX INC·Filed 2005·Granted Mar 3, 2009·123 cites·32 claims
- 1498US7129261B2Cytotoxic agentsMEDAREX INC·Filed 2002·Granted Oct 31, 2006·282 cites·24 claims
- 1598US7087600B2Peptidyl prodrugs and linkers and stabilizers useful thereforMEDAREX INC·Filed 2002·Granted Aug 8, 2006·259 cites·32 claims
- 1698US6989452B2Disulfide prodrugs and linkers and stabilizers useful thereforMEDAREX INC·Filed 2002·Granted Jan 24, 2006·284 cites·21 claims
- 1798US5837243ATherapeutic compounds comprised of anti-Fc receptor antibodiesMEDAREX INC·Filed 1996·Granted Nov 17, 1998·545 cites·18 claims
- 1897US8034959B2Methods of treating cancer with an antibody-drug conjugateMEDAREX INC·Filed 2009·Granted Oct 11, 2011·37 cites·19 claims
- 1997US7714016B2Cytotoxic compounds and conjugates with cleavable substratesMEDAREX INC·Filed 2006·Granted May 11, 2010·45 cites·21 claims
- 2097US7662381B2Interferon alpha receptor 1 antibodies and their usesMEDAREX INC·Filed 2005·Granted Feb 16, 2010·47 cites·20 claims
- 2197US6270765B1Therapeutic compounds comprised of anti-Fc receptor antibodiesMEDAREX INC·Filed 1998·Granted Aug 7, 2001·215 cites·9 claims
- 2296US7977465B2Peptidyl prodrugs and linkers and stabilizers useful thereforMEDAREX INC·Filed 2009·Granted Jul 12, 2011·14 cites·21 claims
- 2396US7968586B2Cytotoxic compounds and conjugatesMEDAREX INC·Filed 2006·Granted Jun 28, 2011·39 cites·18 claims
- 2496US7691962B2Chemical linkers and conjugates thereofMEDAREX INC·Filed 2005·Granted Apr 6, 2010·200 cites·47 claims
- 2596US7456264B2Human monoclonal antibodies against Bacillus anthracis protective antigenMEDAREX INC·Filed 2004·Granted Nov 25, 2008·88 cites·32 claims
- 2696US7452535B2Methods of treatment using CTLA-4 antibodiesMEDAREX INC·Filed 2003·Granted Nov 18, 2008·70 cites·18 claims
- 2796US6303755B1Therapeutic multispecific compounds comprised of anti-FCA receptor antibodiesMEDAREX INC·Filed 1999·Granted Oct 16, 2001·116 cites·17 claims
- 2896US6063116AModulation of cell proliferation and wound healingMEDAREX INC·Filed 1995·Granted May 16, 2000·259 cites·15 claims
- 2995US7875278B2Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residuesMEDAREX INC·Filed 2006·Granted Jan 25, 2011·56 cites·14 claims
- 3095US7847105B2Methods and compounds for preparing CC-1065 analogsMEDAREX INC·Filed 2006·Granted Dec 7, 2010·33 cites·15 claims
- 3195US7476513B2Monoclonal antibody specific for the extracellular domain of prostate specific membrane antigenMEDAREX INC·Filed 2005·Granted Jan 13, 2009·29 cites·16 claims
- 3295US7387776B2Human monoclonal antibodies against CD30MEDAREX INC·Filed 2003·Granted Jun 17, 2008·70 cites·15 claims
- 3395US7135287B1Human antibodiesMEDAREX INC·Filed 2000·Granted Nov 14, 2006·62 cites·12 claims
- 3495US5833985ABispecific molecules for use in inducing antibody dependent effector cell-mediated cytotoxicityMEDAREX INC·Filed 1995·Granted Nov 10, 1998·163 cites·8 claims
- 3594US8383118B2Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1MEDAREX INC·Filed 2006·Granted Feb 26, 2013·24 cites·11 claims
- 3694US7465446B2Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of diseaseMEDAREX INC·Filed 2004·Granted Dec 16, 2008·52 cites·19 claims
- 3794US7329507B2Prodrug compounds with isoleucineMEDAREX INC·Filed 2006·Granted Feb 12, 2008·27 cites·5 claims
- 3894US7115573B2Prodrug compounds with an isoleucineMEDAREX INC·Filed 2001·Granted Oct 3, 2006·61 cites·41 claims
- 3994US6962981B1Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigenMEDAREX INC·Filed 2000·Granted Nov 8, 2005·52 cites·20 claims
- 4093US7744875B2Surrogate therapeutic endpoint for anti-CTLA-4 based immunotherapy of diseaseMEDAREX INC·Filed 2008·Granted Jun 29, 2010·16 cites·10 claims
- 4193US7214663B2Tripeptide prodrug compoundsMEDAREX INC·Filed 2001·Granted May 8, 2007·52 cites·26 claims
- 4293US6897034B2CD10-activated prodrug compoundsMEDAREX INC·Filed 2002·Granted May 24, 2005·52 cites·10 claims
- 4393US6410690B1Therapeutic compounds comprised of anti-Fc receptor antibodiesMEDAREX INC·Filed 1995·Granted Jun 25, 2002·91 cites·17 claims
- 4493US6365161B1Therapeutic compounds comprised of anti-FC receptor binding agentsMEDAREX INC·Filed 1999·Granted Apr 2, 2002·113 cites·20 claims
- 4592US6682928B2Cells expressing anti-Fc receptor binding componentsMEDAREX INC·Filed 1998·Granted Jan 27, 2004·89 cites·24 claims
- 4691US8802632B2Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereofMEDAREX INC·Filed 2013·Granted Aug 12, 2014·12 cites·13 claims
- 4791US7425541B2Enzyme-cleavable prodrug compoundsMEDAREX INC·Filed 2001·Granted Sep 16, 2008·37 cites·23 claims
- 4891US7192582B2Human monoclonal antibodies to FC alpha receptor (CD89)MEDAREX INC·Filed 2002·Granted Mar 20, 2007·52 cites·16 claims
- 4990US8034787B2Enzyme-cleavable prodrug compoundsMEDAREX INC·Filed 2008·Granted Oct 11, 2011·8 cites·17 claims
- 5090US7576258B2Transgenic transchromosomal rodents for making human antibodiesMEDAREX INC·Filed 2005·Granted Aug 18, 2009·7 cites·10 claims
Showing the top 50 of 109 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →